In Brief: Pacific Biometrics, Inc.
This article was originally published in The Gray Sheet
Pacific Biometrics, Inc.: Completes pilot clinical studies on its non-invasive Osteopatch used in the diagnosis of osteoporotic disease. The patch is affixed to the patient's skin to collect sweat samples, which are used in "the dectection of biochemical markers of bone loss," the Irvine, California firm says. Pacific Biometrics has signed up several U.S. medical centers as sites for its upcoming clinical trials, which are expected to include 300 subjects. The company plans to submit a 510(k) once the studies are completed...
You may also be interested in...
Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.
Paracetamol, acetylcysteine and loperamide among list of OTC drugs deemed "essential" by Spain in the fight against coronavirus.
Mylan, in partnership with Indian firm Lupin, will be looking to rival Biogen and Sandoz by introducing an etanercept biosimilar in European markets following a positive opinion by the EMA’s CHMP on Mylan's application.